ResMed Short-term debt remained flat by 0.0% to $260.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2500.0%, from $10.00M to $260.00M. Over 3 years (FY 2022 to FY 2025), Short-term debt shows relatively stable performance with a 0.0% CAGR.
other_short_term_debt_gross_5caa8b| Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $260.00M | $260.00M | $260.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | >999% | >999% | >999% |